Overview

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

Status:
Recruiting
Trial end date:
2025-04-18
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3295668 erbumine is safe in participants with relapsed/refractory neuroblastoma.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Collaborators:
Innovative Therapies for Children with Cancer in Europe (ITCC)
New Approaches to Neuroblastoma Therapy Consortium (NANT)
Treatments:
Cyclophosphamide
Topotecan